Sign up to save your podcasts
Or
Share Marwan Sabbagh, MD, FAAN, CCRI - Expert Perspectives on the Early Diagnosis of Alzheimer’s Disease and the Promise of Novel Therapies on the Horizon
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Marwan Sabbagh, MD, FAAN, CCRI - Expert Perspectives on the Early Diagnosis of Alzheimer’s Disease and the Promise of Novel Therapies on the Horizon
Go online to PeerView.com/FMQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Alzheimer’s disease (AD) is a devastating yet highly prevalent condition, affecting 10% of people older than 65 years and increasing in global prevalence as the world’s population ages. Given the heavy economic and societal burdens of AD, major emphasis has been placed on finding disease-modifying therapies that can successfully delay or prevent the progression of AD. Although several hypotheses have been proposed regarding the causes of AD, the amyloid cascade hypothesis and the tau propagation hypothesis have gained the most support, and there are many novel agents under investigation for the treatment of AD that target Aβ or tau in a variety of ways. Recent advances have also been made in identifying and testing biomarkers for AD that may aid in the early diagnosis of disease, facilitate patient selection for treatment, and monitor therapeutic response. This accredited PeerView on-demand activity is based on a virtual meeting that utilized the innovative Pando™ platform. A multidisciplinary panel of AD experts provides an engaging discussion on the early recognition and diagnosis of AD, current and emerging treatment options and biomarkers, and optimal multidisciplinary management of patients with AD. They also explore ways in which different members of the multidisciplinary team can help to accommodate the influx of new treatable patients that will flood the healthcare system once a disease-modifying therapy is approved for AD. Upon completion of this activity, participants will be able to: Describe the rationale for screening for mild cognitive impairment (MCI) to identify patients at risk for AD early in the disease course, Apply validated neuroimaging techniques and biomarkers to make etiologically based diagnoses of AD, Assess key data sets on the efficacy, safety, and tolerability of available and emerging therapies for the treatment of AD, Employ a multidisciplinary team-based approach to manage the influx of patients that will need to be screened, diagnosed, and treated once a disease-modifying therapy is approved in AD.
View all episodes
By PVI, PeerView Institute for Medical Education
4
44 ratings
Go online to PeerView.com/FMQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Alzheimer’s disease (AD) is a devastating yet highly prevalent condition, affecting 10% of people older than 65 years and increasing in global prevalence as the world’s population ages. Given the heavy economic and societal burdens of AD, major emphasis has been placed on finding disease-modifying therapies that can successfully delay or prevent the progression of AD. Although several hypotheses have been proposed regarding the causes of AD, the amyloid cascade hypothesis and the tau propagation hypothesis have gained the most support, and there are many novel agents under investigation for the treatment of AD that target Aβ or tau in a variety of ways. Recent advances have also been made in identifying and testing biomarkers for AD that may aid in the early diagnosis of disease, facilitate patient selection for treatment, and monitor therapeutic response. This accredited PeerView on-demand activity is based on a virtual meeting that utilized the innovative Pando™ platform. A multidisciplinary panel of AD experts provides an engaging discussion on the early recognition and diagnosis of AD, current and emerging treatment options and biomarkers, and optimal multidisciplinary management of patients with AD. They also explore ways in which different members of the multidisciplinary team can help to accommodate the influx of new treatable patients that will flood the healthcare system once a disease-modifying therapy is approved for AD. Upon completion of this activity, participants will be able to: Describe the rationale for screening for mild cognitive impairment (MCI) to identify patients at risk for AD early in the disease course, Apply validated neuroimaging techniques and biomarkers to make etiologically based diagnoses of AD, Assess key data sets on the efficacy, safety, and tolerability of available and emerging therapies for the treatment of AD, Employ a multidisciplinary team-based approach to manage the influx of patients that will need to be screened, diagnosed, and treated once a disease-modifying therapy is approved in AD.
More shows like PeerView Neuroscience & Psychiatry CME/CNE/CPE Video Podcast
View all
PeerView Endocrinology & Diabetes CME/CNE/CPE Audio Podcast
6 Listeners
PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast
3 Listeners
PeerView Gastroenterology CME/CNE/CPE Audio Podcast
3 Listeners
PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio Podcast
10 Listeners
PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast
5 Listeners
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
28 Listeners
PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
9 Listeners
PeerView Gastroenterology CME/CNE/CPE Video Podcast
3 Listeners
PeerView Internal Medicine CME/CNE/CPE Video Podcast
2 Listeners
PeerView Endocrinology & Diabetes CME/CNE/CPE Video Podcast
3 Listeners
PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast
3 Listeners
PeerView Infectious Diseases CME/CNE/CPE Audio Podcast
5 Listeners
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast
5 Listeners
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast
2 Listeners
PeerView Infectious Diseases CME/CNE/CPE Video Podcast
0 Listeners
PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
9 Listeners
PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast
2 Listeners
PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
10 Listeners
PeerView Clinical Pharmacology CME/CNE/CPE Video
2 Listeners